On August 7, according to Lenovo Venture Capital, Chengdu Zhongkeoge Biotechnology Co., Ltd., an enterprise in the field of xenograft in China, announced the completion of the A3 round of financing exceeding 200 million yuan in August 2026. This round of financing was led by China Science and Technology Innovation Star, followed by Lenovo Venture Capital, Muyuan Group, Weigaojing, Huali Group, Huafang Capital, and Chengdu Science and Technology Venture Capital. The old shareholders Betta Fund and Guanghe Venture Capital continued to raise capital. Kaicheng Capital acted as the exclusive financial advisor. This round of funding will mainly be used for clinical trial declaration and promotion of xenograft products, expansion of DPF grade medical donor pig production capacity, industrial base construction, and development of a new generation of multi-gene edited donor pigs.

On August 7, according to Lenovo Venture Capital, Chengdu Zhongkeoge Biotechnology Co., Ltd., an enterprise in the field of xenograft in China, announced the completion of the A3 round of financing exceeding 200 million yuan in August 2026. This round of financing was led by China Science and Technology Innovation Star, followed by Lenovo Venture Capital, Muyuan Group, Weigaojing, Huali Group, Huafang Capital, and Chengdu Science and Technology Venture Capital. The old shareholders Betta Fund and Guanghe Venture Capital continued to raise capital. Kaicheng Capital acted as the exclusive financial advisor. This round of funding will mainly be used for clinical trial declaration and promotion of xenograft products, expansion of DPF grade medical donor pig production capacity, industrial base construction, and development of a new generation of multi-gene edited donor pigs.